文献速递类风湿关节炎

干扰素-α介导的早期类风湿关节炎治疗抵抗涉及表观遗传重编程

Interferon-α-mediated therapeutic resistance in early rheumatoid arthritis implicates epigenetic reprogramming.
PubMed 文献 · Ann Rheum Dis · 2022-08-11

在多中心191例早期未治疗类风湿关节炎患者中,验证基线干扰素基因特征(IGS)升高可预测6个月临床结局变差,且IGS反映循环IFN-α蛋白水平;CD4+ T和CD19+ B细胞存在差异甲基化CpG位点及疾病相关基因表达失调,提示IFN-α通过表观遗传机制介导持续致病性淋巴细胞活化。

要点

  • 基线IGS升高独立预测6个月DAS-28更高(p=0.025)及EULAR良好临床应答可能性更低(p=0.034)。
  • 基线至6个月IGS与IFN-α水平均显著下降(两者p<0.0001)。
  • CD4+ T和CD19+ B细胞差异甲基化CpG位点及PARP9、STAT1、EPSTI1表达失调与基线IGS/IFNα相关。

核心结论

  • 在早期类风湿关节炎中,IFN-α可能引起持续性、表观遗传介导的致病性淋巴细胞活化与增殖增加,IGS因此是稳健的预后生物标志物。
  • IFN-α的持续有害效应为对部分早期类风湿关节炎患者初始靶向IFN-α治疗提供了依据。

研究设计与样本

  • 多中心起始队列研究,纳入191例早期未治疗类风湿关节炎患者,检测全血IGS(MxA、IFI44L、OAS1、IFI6、ISG15)并参考循环IFN蛋白、临床结局及对循环CD19+ B和CD4+ T淋巴细胞的表观遗传影响。

主要发现

  • 复现了既往发现,显示基线IGS升高。
  • 首次显示早期类风湿关节炎中IGS反映循环IFN-α蛋白。
  • 配对纵向分析显示基线至6个月IGS与IFN-α水平均显著下降(两者p<0.0001)。
  • 基线IGS升高预测6个月临床结局更差,包括DAS-28更高(p=0.025)及EULAR良好临床应答可能性更低(p=0.034),且独立于其他常规疾病活动度与临床应答预测因素。
  • CD4+ T细胞和CD19+ B细胞分子分析显示差异甲基化CpG位点及疾病相关基因(包括PARP9、STAT1、EPSTI1)表达失调与基线IGS/IFNα水平相关;差异甲基化CpG位点提示B细胞(GATA3、ETSI、NFATC2、EZH2)和T细胞(p300、HIF1α)转录因子结合改变。

关键数值与推荐

  • 基线IGS升高预测6个月DAS-28更高(p=0.025)。
  • 基线IGS升高预测6个月EULAR良好临床应答可能性更低(p=0.034)。
  • 基线至6个月IGS与IFN-α水平均显著下降(两者p<0.0001)。

临床怎么用

  • 原文结论提示IGS是稳健的预后生物标志物。
  • 原文结论认为IFN-α的持续有害效应为对部分早期类风湿关节炎患者初始靶向IFN-α治疗提供了依据。
  • 原文未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: An interferon (IFN) gene signature (IGS) is present in approximately 50% of early, treatment naive rheumatoid arthritis (eRA) patients where it has been shown to negatively impact initial response to treatment. We wished to validate this effect and explore potential mechanisms of action. METHODS: In a multicentre inception cohort of eRA patients (n=191), we examined the whole blood IGS (MxA, IFI44L, OAS1, IFI6, ISG15) with reference to circulating IFN proteins, clinical outcomes and epigenetic influences on circulating CD19+ B and CD4+ T lymphocytes. RESULTS: We reproduced our previous findings demonstrating a raised baseline IGS. We additionally showed, for the first time, that the IGS in eRA reflects circulating IFN-α protein. Paired longitudinal analysis demonstrated a significant reduction between baseline and 6-month IGS and IFN-α levels (p<0.0001 for both). Despite this fall, a raised baseline IGS predicted worse 6-month clinical outcomes such as increased disease activity score (DAS-28, p=0.025) and lower likelihood of a good EULAR clinical response (p=0.034), which was independent of other conventional predictors of disease activity and clinical response. Molecular analysis of CD4+ T cells and CD19+ B cells demonstrated differentially methylated CPG sites and dysregulated expression of disease relevant genes, including PARP9, STAT1, and EPSTI1, associated with baseline IGS/IFNα levels. Differentially methylated CPG sites implicated altered transcription factor binding in B cells (GATA3, ETSI, NFATC2, EZH2) and T cells (p300, HIF1α). CONCLUSIONS: Our data suggest that, in eRA, IFN-α can cause a sustained, epigenetically mediated, pathogenic increase in lymphocyte activation and proliferation, and that the IGS is, therefore, a robust prognostic biomarker. Its persistent harmful effects provide a rationale for the initial therapeutic targeting of IFN-α in selected patients with eRA.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Cooles FAH, Tarn J, Lendrem DW, et al. Interferon-α-mediated therapeutic resistance in early rheumatoid arthritis implicates epigenetic reprogramming. Ann Rheum Dis. 2022. PMID: 35680389. doi:10.1136/annrheumdis-2022-222370

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。